Prana Receives Approval for 12-Month Open-Label Extension

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Prana Receives Approval for 12-Month Open-Label Extension Study in Alzheimer's Disease

MELBOURNE, AUSTRALIA--(Marketwired - Jul 3, 2013) -  Prana Biotechnology ( NASDAQ : PRAN ) ( ASX : PBT ) today announced that it has received approval from the Austin Health Human Research Ethics Committee (HREC) to commence a 12-month open-label extension study with Alzheimer's Disease patients participating in Prana's IMAGINE trial.

The approval follows a full review by Austin Health HREC of the potential benefit to patients and safety data collected during the ongoing IMAGINE trial, a 12-month double-blind Phase II clinical trial of PBT2 in Alzheimer's patients. Fifteen percent of participants in IMAGINE have now finished the full 12 months of treatment and one hundred percent have completed at least 6 months of treatment.

Patients who have completed the full 12-month term of the IMAGINE trial are eligible for participation in the open-label extension study. All participants in the extension study will receive a 250mg once daily oral dose of PBT2 for an additional 12 months, with the first patient expected to start next month. 

Prana's Chairman and CEO, Geoffrey Kempler, said, "We are keenly looking forward to the completion of the current IMAGINE trial to see the effects of PBT2 over 12 months, and we expect to report the results in March 2014. This will allow us to take the steps necessary to progress the commercialisation of PBT2 for Alzheimer's. What is so helpful about the open-label study is that it will provide ongoing information to support the safety, tolerability and efficacy of PBT2 over a 24-month period."

The open-label extension study protocol will closely follow the IMAGINE protocol, measuring amyloid burden and physical changes in the brains of Alzheimer's patients, through PET imaging, MRI and FDG-PET, as well as cognition and function. The protocol synopsis appears below in Appendix 1.

About Prana Biotechnology Limited Prana Biotechnology was established to commercialise research into age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

For further information please visit the Company's web site at www.pranabio.com .

Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

Appendix 1:

Open Label Extension Trial Synopsis

Title An open-label extension study to assess the safety and tolerability of PBT2, and its effect on amyloid deposition in the brains of Patients with prodromal or mild Alzheimer's disease.
Study Number PBT2-204-Ext
Study Name/Acronym IMAGINE Extension
Study Design Open-label, non-randomised, extension study of the PBT2-204 IMAGINE Study.
Objectives Prodromal or mild Alzheimer's disease patients were entered on IMAGINE. Following 52 weeks of treatment with either 250mg of PBT2 or placebo, they may now proceed to the extension study. Primary objective : To evaluate the effect after 52 weeks of treatment with 250mg of PBT2 on: • Safety and tolerability, and • Brain amyloid levels.
  Secondary objectives : To evaluate the effect after 52 weeks of treatment with 250mg of PBT2 on: • Brain metabolic activity • Brain volumes • Cognition • Functional abilities • Blood biomarkers.
Number of Patients Approximately 40 Patients who have completed Visit 10 (Week 52) of the PBT2-204 clinical trial.
Key Patient Criteria Must have completed Visit 10 (Week 52) of the PBT2-204 clinical trial.
Doses 250mg PBT2 capsules, once daily
Per Patient Duration 56+ weeks: Screening period (1 week, if required), Treatment Period (52 weeks) and Follow-up Period (4 weeks) post last dose of PBT2.
Endpoints Primary • 11 C-PiB PET neocortical SUVR •  Safety and Tolerability assessments. Secondary • MRI: Total brain, hippocampal and ventricular volumes • 18 F-FDG PET: SUVR • Cognition: NTB and MMSE • Function: ADCS-ADL-23 • Blood biomarkers: A-beta oligomer
Trial Locations • Australia
Trial Standard Study will be conducted according to ICH GCP

Contacts: USA: Christopher Chu Grayling Christopher.chu@grayling.com or Vivian Chen Grayling Vivian.Chen@grayling.com (646) 284-9400

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 73

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 21

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 44

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 96

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 40

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking AI Potential: VERSES Genius™ Surpasses Competitors

Updated Category News Views 353

VERSES Genius™ Agent Sets New Benchmark in AI Performance VERSES AI Inc., a pioneer in cognitive computing, is redefining intelligent systems with its innovative Genius™ toolkit. Recent evaluations against industry-leading benchmarks highlight its significant advancements in artificial intelligence. The preliminary results regarding the "Atari 100K Challenge" showcase...

Continue Reading
MKS Instruments Achieves Loan Repricing and Adds Prepayment

Updated Category News Views 356

MKS Instruments Achieves Loan Repricing and Adds Prepayment MKS Instruments, Inc. (NASDAQ: MKSI), a prominent global leader in enabling technologies, has made a significant leap in optimizing its financial structure. Recently, the company announced it has completed the repricing of its considerable secured tranche B term loans, which amount to a staggering $2.5 billion...

Continue Reading
Incredible Growth of Cheniere Energy: A 15-Year Journey

Updated Category News Views 238

The Remarkable Performance of Cheniere Energy Cheniere Energy, known by its trading symbol LNG, has consistently outperformed the market over the past 15 years. Investors in LNG have witnessed an incredible annualized return of 35.23%, exceeding the market by 22.77%. Currently, Cheniere Energy boasts a market capitalization of $53.26 billion, marking its growth trajectory...

Continue Reading
Adhara and ioBuilders Form New Powerhouse in Blockchain Solutions

Updated Category News Views 420

Adhara and ioBuilders Unite for Blockchain Innovation Adhara and ioBuilders have merged their expertise to create a leading provider of blockchain software products tailored specifically for financial institutions. This strategic alliance has resulted in a profitable company with a robust workforce of over 120 employees, distributed across various regions including the...

Continue Reading
Legal Action Against Lineage, Inc. Following Significant Stock Drop

Updated Category News Views 227

Overview of the Situation Surrounding Lineage, Inc. In recent times, Lineage, Inc. has found itself at the heart of a significant legal controversy following a dramatic 17% drop in its stock price. Leading with this news is the announcement of a class action lawsuit against the company and some of its top executives. Legal firm Bleichmar Fonti & Auld LLP is rallying...

Continue Reading